132 related articles for article (PubMed ID: 22966891)
1. Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritis.
O'Doherty C; Schnabl M; Spargo L; Cleland LG; James M; Proudman SM; Wiese MD
Pharmacogenomics; 2012 Sep; 13(12):1427-34. PubMed ID: 22966891
[TBL] [Abstract][Full Text] [Related]
2. The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide.
Pawlik A; Herczynska M; Kurzawski M; Safranow K; Dziedziejko V; Drozdzik M
Pharmacogenomics; 2009 Feb; 10(2):303-9. PubMed ID: 19207032
[TBL] [Abstract][Full Text] [Related]
3. Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis.
Wiese MD; Hopkins AM; King C; Wechalekar MD; Lee A; Spargo L; Metcalf R; McWilliams L; Hill C; Cleland LG; Proudman SM
Arthritis Care Res (Hoboken); 2021 Jul; 73(7):983-989. PubMed ID: 32339392
[TBL] [Abstract][Full Text] [Related]
4. Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis.
Grabar PB; Rozman B; Logar D; Praprotnik S; Dolzan V
Ann Rheum Dis; 2009 Aug; 68(8):1367-8. PubMed ID: 19605743
[No Abstract] [Full Text] [Related]
5. Mechanism of action of leflunomide in rheumatoid arthritis.
Fox RI
J Rheumatol Suppl; 1998 Jul; 53():20-6. PubMed ID: 9666414
[TBL] [Abstract][Full Text] [Related]
6. Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial.
Bao C; Chen S; Gu Y; Lao Z; Ni L; Yu Q; Xu J; Li X; Liu J; Sun L; He P; Ma J; Xu S; Ding C
Chin Med J (Engl); 2003 Aug; 116(8):1228-34. PubMed ID: 12935395
[TBL] [Abstract][Full Text] [Related]
7. Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice.
Taniguchi A; Urano W; Tanaka E; Furihata S; Kamitsuji S; Inoue E; Yamanaka M; Yamanaka H; Kamatani N
Pharmacogenet Genomics; 2007 Jun; 17(6):383-90. PubMed ID: 17502830
[TBL] [Abstract][Full Text] [Related]
8. Leflunomide in active rheumatoid arthritis: a prospective study in daily practice.
Van Roon EN; Jansen TL; Mourad L; Houtman PM; Bruyn GA; Griep EN; Wilffert B; Tobi H; Brouwers JR
Br J Clin Pharmacol; 2004 Jun; 57(6):790-7. PubMed ID: 15151525
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis.
Wiese MD; Schnabl M; O'Doherty C; Spargo LD; Sorich MJ; Cleland LG; Proudman SM
Arthritis Res Ther; 2012 Jul; 14(4):R163. PubMed ID: 22784880
[TBL] [Abstract][Full Text] [Related]
10. Leflunomide in clinical practice.
Pinto P; Dougados M
Acta Reumatol Port; 2006; 31(3):215-24. PubMed ID: 17094333
[TBL] [Abstract][Full Text] [Related]
11. Leflunomide in clinical practice. A retrospective observational study on use of leflunomide in New Zealand.
Jagoda JS; Rajapakse CN
Int J Rheum Dis; 2011 Oct; 14(4):340-4. PubMed ID: 22004230
[TBL] [Abstract][Full Text] [Related]
12. The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study.
Flendrie M; Creemers MC; Welsing PM; van Riel PL
Rheumatology (Oxford); 2005 Apr; 44(4):472-8. PubMed ID: 15598707
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide.
Strangfeld A; Hierse F; Kekow J; von Hinueber U; Tony HP; Dockhorn R; Listing J; Zink A
Ann Rheum Dis; 2009 Dec; 68(12):1856-62. PubMed ID: 19126559
[TBL] [Abstract][Full Text] [Related]
14. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
[TBL] [Abstract][Full Text] [Related]
15. Leflunomide and rheumatoid arthritis: new preparation. Neither the safest nor the most effective slow-acting antirheumatic drug.
Prescrire Int; 2001 Apr; 10(52):36-9. PubMed ID: 11718154
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience with leflunomide in rheumatoid arthritis. Leflunomide Investigators' Group.
Rozman B
J Rheumatol Suppl; 1998 Jul; 53():27-32. PubMed ID: 9666415
[TBL] [Abstract][Full Text] [Related]
17. The effect of ESR1 and ESR2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with leflunomide.
Dziedziejko V; Kurzawski M; Safranow K; Chlubek D; Pawlik A
Pharmacogenomics; 2011 Jan; 12(1):41-7. PubMed ID: 21174621
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphisms in metabolic pathways of leflunomide in the treatment of rheumatoid arthritis.
Soukup T; Dosedel M; Nekvindova J; Toms J; Vlcek J; Pavek P
Clin Exp Rheumatol; 2015; 33(3):426-32. PubMed ID: 25664505
[TBL] [Abstract][Full Text] [Related]
19. Leflunomide discontinuation in rheumatoid arthritis and influence of associated disease-modifying anti-rheumatic drugs: a survival analysis.
Rodriguez-Rodriguez L; Jover-Jover JA; Fontsere O; Peña-Blanco RC; León L; Fernández-Gutierrez B; Abásolo L
Scand J Rheumatol; 2013; 42(6):433-6. PubMed ID: 23742043
[TBL] [Abstract][Full Text] [Related]
20. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
James HM; Gillis D; Hissaria P; Lester S; Somogyi AA; Cleland LG; Proudman SM
J Rheumatol; 2008 Apr; 35(4):562-71. PubMed ID: 18322994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
